What is the Price Targets for Marrone Bio Innovations Inc. (MBII)?

Marrone Bio Innovations Inc. (NASDAQ:MBII) saw an upside of 7.90% to close Friday at $0.97 after adding $0.07 on the day. The 5-day average trading volume is 3,665,820 shares of the company’s common stock. It has gained $1.0000 in the past week and touched a new high 1 time within the past 5 days. An average of 1,369,015 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 826,832.

MBII’s 1-month performance is -3.74% or -$0.0378 on its low of $0.7684 reached on 09/16/21. The company’s shares have touched a 52-week low of $0.77 and high of $2.90, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, MBII has lost -22.22% or -$0.2778 and has reached a new high 12 times. However, the current price is down -66.48%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

On Aug 24, 41 days have gone by since the last insider trading activity for Marrone Bio Innovations Inc. (MBII). Marrone Pamela G (Director) most recently sold 24,510 shares at $1.02 per share on Aug 24. This transaction cost the insider $25,000. Director, Marrone Pamela G, sold 17,858 shares at a price of $1.45 on Aug 09. Then, on Jul 26, Director Marrone Pamela G sold 17,858 shares at a price of $1.40 per share. This transaction amounted to $25,001.

Valuation Metrics

Marrone Bio Innovations Inc. (MBII) has a trailing price-to-earnings (P/E) ratio of 17.64 for the broader industry and 13.01 for the sector, meaning that investors are optimistic about the stock’s future prospects.MBII stock has a beta of 0.27. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.95 while the price-to-book (PB) in the most recent quarter is 4.86.

Marrone Bio Innovations Inc.’s quick ratio for the period ended June 29 was 1.30, with the current ratio over the same period at 1.50 meaning that MBII stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.54, while the total debt to equity was 0.89. In terms of profitability, the gross margin trailing 12 months is 61.40%The trailing 12-month EBITDA margin is -33.43% while for the period ending June 29; Marrone Bio Innovations Inc.’s operating margin was -37.30%. The firm’s gross profit as reported stood at $22.87 million against revenue of $38.37 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 3.33% to $12.6 million, while revenue of $11.04 million was 12.38% off the previous quarter. Analysts expected MBII to announce -$0.01 per share in earnings in its latest quarter, but it posted -$0.02, representing a -100.00% surprise. EBITDA for the quarter stood at more than -$1.21 million. MBII stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 50.94 million, with total debt at $34.68 million. Shareholders hold equity totaling $176.28 million

Technical Picture

Let’s look briefly at Marrone Bio Innovations Inc. (MBII) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 54.40% to suggest the stock is trending Neutral, with historical volatility in this time period at 93.44%.

The stock’s 5-day moving average is $0.9445, reflecting a -1.70% or -$0.0168 change from its current price. MBII is currently trading -2.78% above its 20-day SMA, -36.87% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -33.41% and -20.31% respectively.

Stochastic %K and %D was 64.97% and 66.24% and the average true range (ATR) pointed at 0.0816. The RSI (14) points at 48.90%, while the 14-day stochastic is at 81.00% with the period’s ATR at 0.0794. The stock’s 9-day MACD Oscillator is pointing at -0.0061 and 0.0231 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Marrone Bio Innovations Inc. (NASDAQ: MBII), Canaccord Genuity launched coverage with a Buy rating.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam